• +41 91 682 20 40
  • info@elixi-int.com
  • Reserved Area
    • Login
    • Register
    • Request Document
    • Send Document
logo
  • Home
  • About Us
  • Services
  • Quality
  • News
  • Case Studies
  • Contact

Let's talk

info@yourwebsite.com
+1 (555) 123-4567

  • Search

Elixi

16 January 2023

Fabio Macchi is our new Head of Medical and Quality Departments.


0 Comments1 Minute

30 March 2022

Carvykti (ciltacabtagene autoleucel), new gene therapy to treat adult patients with multiple myeloma


0 Comments3 Minutes

11 March 2022

Jardiance (empagliflozin)approved for Wider Range of Patients with Heart Failure


0 Comments3 Minutes

9 March 2022

Kimmtrak (tebentafusp), a monotherapy for the treatment of adult patients with uveal melanoma, a rare type of eye cancer.


0 Comments3 Minutes

7 February 2022

Breyanzi (lisocabtagene maraleucel) New gene therapy treatment for patients with relapsed or refractory large B-cell lymphoma


0 Comments4 Minutes

3 November 2021

Cyltezo(adalimumab-adbm), the First Interchangeable Biosimilar to Humira


0 Comments3 Minutes

25 October 2021

Trodelvy (sacituzumab govitecan), First-in-class medicine to treat aggressive form of breast cancer


0 Comments3 Minutes

21 September 2021

Byooviz (ranibizumab-nuna), First Biosimilar to Treat Macular Degeneration Disease and Other Eye Conditions


0 Comments3 Minutes

18 June 2021

Astepro (azelastine hydrochloride nasal spray, 0.15%), nasal antihistamine approved for nonprescription use


0 Comments2 Minutes

8 June 2021

Aduhelm (aducanumab), first new Alzheimer’s drug in 20 years.


0 Comments5 Minutes

  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 13